Detalles de la búsqueda
1.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
; 183(2): 419-428, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32683565
2.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 20(9): 1226-1238, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31402321
3.
[Palbociclib combinations as new therapeutic strategies in the treatment of HR+/HER2- advanced breast cancer]. / Palbociclib kombinációs kezelések: új kezelési stratégiák a HR+/HER2 elõrehaladott emlõrák terápiájában.
Magy Onkol
; 61(2): 167-173, 2017 Jun 06.
Artículo
en Húngaro
| MEDLINE | ID: mdl-28585619
4.
[Experience with cabazitaxel therapy for patients with metastatic castrate resistant prostate cancer in Hungary]. / Hazai tapasztalatok kasztrációrezisztens metasztatikus prosztatadaganatos betegek kabazitaxelterápiájával.
Magy Onkol
; 61(4): 353-360, 2017 Dec 18.
Artículo
en Húngaro
| MEDLINE | ID: mdl-29257155
5.
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Breast Cancer Res
; 18(1): 67, 2016 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27349747
6.
[Systemic therapy of breast cancer: practice guideline]. / Az emlõrák szisztémás kezelése: szakmai útmutatás.
Magy Onkol
; 60(3): 241-57, 2016 09.
Artículo
en Húngaro
| MEDLINE | ID: mdl-27579723
7.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Lancet Oncol
; 16(1): 25-35, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25524798
8.
[Clinical use of 18F-FDG PET/CT in colorectal carcinoma]. / 18F-FDG PET/CT klinikai alkalmazása colorectalis carcinomában.
Orv Hetil
; 154(37): 1447-53, 2013 Sep 15.
Artículo
en Húngaro
| MEDLINE | ID: mdl-24016751
9.
[Diabetes in patients with malignant tumors]. / Diabetes daganatos betegségben.
Magy Onkol
; 57(3): 177-81, 2013 Sep.
Artículo
en Húngaro
| MEDLINE | ID: mdl-24107824
10.
Corrigendum: Systemic treatment of breast cancer. 1st Central-Eastern European professional Consensus Statement on breast cancer.
Pathol Oncol Res
; 29: 1610954, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36798671
11.
Opposite trends in incidence of breast cancer in young and old female cohorts in Hungary and the impact of the Covid-19 pandemic: a nationwide study between 2011-2020.
Front Oncol
; 13: 1182170, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37795445
12.
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
Invest New Drugs
; 30(2): 681-7, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20830502
13.
Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.
Pathol Oncol Res
; 28: 1610383, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35898593
14.
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
Invest New Drugs
; 29(5): 1021-8, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20127139
15.
Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2- Advanced Breast Cancer: A Nationwide Real-World Experience.
Onco Targets Ther
; 14: 3971-3981, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34234466
16.
Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience.
Pathol Oncol Res
; 27: 1609785, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34257621
17.
[Adjuvant chemotherapy of early stage breast cancer]. / A gyógyszeres kezelés szerepe a korai emlôrák kezelésében.
Orv Hetil
; 151(9): 344-53, 2010 Feb 28.
Artículo
en Húngaro
| MEDLINE | ID: mdl-20159750
18.
[Systemic treatment of breast cancer: professional guideline]. / Az emlorák szisztémás kezelése: szakmai irányelvek.
Magy Onkol
; 64(4): 348-368, 2020 Dec 14.
Artículo
en Húngaro
| MEDLINE | ID: mdl-33313610
19.
Advantages of 18F FDG-PET/CT over Conventional Staging for Sarcoma Patients.
Pathol Oncol Res
; 25(1): 131-136, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28994004
20.
Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumours by histamine.
Eur J Cell Biol
; 87(4): 227-36, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18258331